Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase i trial in patients with advanced solid tumors: A California Cancer Consortium trial

Robert J. Morgan, Timothy W. Synold, Jeffrey A. Longmate, David I. Quinn, David R Gandara, Heinz Josef Lenz, Christopher Ruel, Bixin Xi, Michael D. Lewis, A. Dimitrios Colevas, James Doroshow, Edward M. Newman

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase i trial in patients with advanced solid tumors: A California Cancer Consortium trial'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds